QQ客服 官方微博 反馈留言

	First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
	Zhang, L.[1]; Huang, Y.[1]; Yang, Y.[1]; Ma, S.[1]; Lin, X.[2]; Lin, L.[3]; Zhou, T.[4]; Deng, Y.[5]; Zhang, C.[6]; Ding, X.[7]
会议日期	SEP 08-12, 2017
会议地点	Madrid, SPAIN
URL标识	查看原文
内容类型	会议论文
URI标识	http://www.corc.org.cn/handle/1471x/4760444
专题	暨南大学
作者单位	1.[1]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China 2.[2]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Oncol, Guangzhou, Guangdong, Peoples R China 3.[3]Guangdong Univ Tradit Chinese Med, Affiliated Hosp 1, Oncol, Guangzhou, Guangdong, Peoples R China 4.[4]Guangzhou Med Univ, Canc Ctr, Radiat Oncol, Guangzhou, Guangdong, Peoples R China 5.[5]Foshan FirstPeople Hosp, Oncol, Foshan, Peoples R China 6.[6]Dongguan People Hosp, Radiat Oncol, Dongguan, Peoples R China 7.[7]Sun Yat Sen Univ, Affiliated Jiangmen Hosp, Jiangmen Cent Hosp, Med Oncol, Jiangmen, Peoples R China 8.[8]Peking Univ, Shenzhen Hosp, Oncol, Shenzhen, Peoples R China 9.[9]Guangxi Med Univ, Affiliated Hosp 1, Radiat Oncol, Guangxi, Peoples R China 10.[10]Peoples Hosp Guangxi Zhuang Autonomous Reg, Oncol, Guangxi, Peoples R China
推荐引用方式 GB/T 7714	Zhang, L.[1],Huang, Y.[1],Yang, Y.[1],et al. First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial[C]. 见:. Madrid, SPAIN. SEP 08-12, 2017.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。